Skip to main content
. 2016 May 24;6:26456. doi: 10.1038/srep26456

Figure 6. MLN9708 enhances the cytotoxic effects of doxorubicin (Dox) in breast cancer cells.

Figure 6

(a–h) Breast cancer cells (T-47D, MCF7, MDA-MB-361, SK-BR-3, HCC1954, MDA-MB-468, MDA-MB-231, and BT-549) were treated with Dox at the indicated concentrations with or without MLN9708 (0.1 μM [0.3 μM for BT-549 cells]) for 48 h. Cell viability was then measured by Cell Counting Kit-8 (CCK-8) assay. Data were represented as means ± standard deviations (SD). *P < 0.05, **P < 0.01, and ***P < 0.001 (t-test).